Arvinas Announces Changes to its Board of Directors
NEW HAVEN, Conn., June 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein…
Browsing Tag
Arvinas
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable…
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all…
Arvinas to Present at Upcoming Investor Conferences
NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein…
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2…
– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – –…